Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Early-Phase 18F-Florbetapir and 18F-Flutemetamol Images as Proxies of Brain Metabolism in a Memory Clinic Setting
Univ Geneva, Geneva Univ, Neuroctr, Lab Neuroimaging & Innovat Mol Tracers NIMTlab, Geneva, Switzerland.;Univ Geneva, Fac Med, Geneva, Switzerland.;Univ Vita Salute San Raffaele, Milan, Italy.;IRCCS, San Raffaele Sci Inst, Div Neurosci, In Vivo Human Mol & Struct Neuroimaging Unit, Milan, Italy..
Univ Geneva, Geneva Univ, Neuroctr, Lab Neuroimaging & Innovat Mol Tracers NIMTlab, Geneva, Switzerland.;Univ Geneva, Fac Med, Geneva, Switzerland..ORCID iD: 0000-0002-3033-8817
Univ Geneva, Lab Neuroimaging Aging LANVIE, Geneva, Switzerland.;Geneva Univ Hosp, Memory Clin, Geneva, Switzerland..
Geneva Univ Hosp, Diagnost Dept, Div Radiol, Geneva, Switzerland..
Show others and affiliations
2023 (English)In: Journal of Nuclear Medicine, ISSN 0161-5505, E-ISSN 1535-5667, Vol. 64, no 2, p. 266-273Article in journal (Refereed) Published
Abstract [en]

Alzheimer disease (AD) neuropathologic changes are 6-amyloid (A6) deposition, pathologic tau, and neurodegeneration. Dual-phase amy-loid PET might be able to evaluate A6 deposition and neurodegenera-tion with a single tracer injection. Early-phase amyloid PET scans provide a proxy for cerebral perfusion, which has shown good correla-tions with neural dysfunction measured through metabolic consump-tion, whereas the late frames depict amyloid distribution. Our study aimed to assess the comparability between early-phase amyloid PET scans and 18F-FDG PET brain topography at the individual level and their ability to discriminate patients. Methods: One hundred sixty-six subjects evaluated at the Geneva Memory Center, ranging from no cognitive impairment to mild cognitive impairment and dementia, underwent early-phase amyloid PET-using either 18F-florbetapir (eFBP) (n = 94) or 18F-flutemetamol (eFMM) (n = 72)-and 18F-FDG PET. A6 status was assessed. SUV ratios (SUVRs) were extracted to evaluate the correlation of eFBP/eFMM and their respective 18F-FDG PET scans. The single-subject procedure was applied to investigate hypometabolism and hypoperfusion maps and their spatial overlap by the Dice coefficient. Receiver-operating-characteristic analyses were performed to compare the discriminative power of eFBP/eFMM and 18F-FDG PET SUVR in AD-related meta-regions of interest between A6-negative healthy controls and cases in the AD continuum. Results: Positive correlations were found between eFBP/eFMM and 18F-FDG PET SUVR independently of A6 status and A6 radiotracer (R> 0.72, P< 0.001). eFBP/eFMM single-subject analysis revealed clusters of significant hypoperfusion with good correspondence to hypometabo-lism topographies, independently of the underlying neurodegenerative patterns. Both eFBP/eFMM and 18F-FDG PET SUVR significantly dis-criminated AD patients from controls in the AD-related meta-regions of interest (eFBP area under the curve [AUC], 0.888; eFMM AUC, 0.801), with 18F-FDG PET performing slightly better, although not sig-nificantly (all P values higher than 0.05), than others (18F-FDG AUC, 0.915 and 0.832 for subjects evaluated with eFBP and eFMM, respec-tively). Conclusion: The distribution of perfusion was comparable to that of metabolism at the single-subject level by parametric analysis, particularly in the presence of a high neurodegeneration burden. Our findings indicate that eFBP and eFMM imaging can replace 18F-FDG PET imaging, as they reveal typical neurodegenerative patterns or allow exclusion of the presence of neurodegeneration. The findings show cost-saving capacities of amyloid PET and support routine use of the modality for individual classification in clinical practice.

Place, publisher, year, edition, pages
The Society of Nuclear Medicine and Molecular Imaging , 2023. Vol. 64, no 2, p. 266-273
Keywords [en]
neurodegeneration, early-phase amyloid PET, 18F-FDG PET, individual maps
National Category
Radiology, Nuclear Medicine and Medical Imaging Neurology
Identifiers
URN: urn:nbn:se:uu:diva-503657DOI: 10.2967/jnumed.122.264256ISI: 000976419900015PubMedID: 35863896OAI: oai:DiVA.org:uu-503657DiVA, id: diva2:1765148
Funder
EU, Horizon 2020, 667375Available from: 2023-06-09 Created: 2023-06-09 Last updated: 2023-06-09Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Peretti, Debora ElisaHaller, Sven
By organisation
Radiology
In the same journal
Journal of Nuclear Medicine
Radiology, Nuclear Medicine and Medical ImagingNeurology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 26 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf